Mednax, Inc. (NYSE: MD)
Hagens Berman Sobol Shapiro LLP alerts investors in Mednax, Inc. (NYSE: MD) to the September 10, 2018 Lead Plaintiff deadline in the securities class action pending in the U.S. District Court for the Southern District of Florida.
If you purchased or otherwise acquired shares of MD between between February 4, 2016 and July 27, 2017 and suffered losses contact Hagens Berman Sobol Shapiro LLP. For more information, contact Reed Kathrein, who is leading the firm's investigation, by calling 510-725-3000 or emailing MD@hbsslaw.com.
On July 28, 2017, Defendants announced during Mednax’s second quarter earnings call with investors and analysts that (1) Mednax did not complete any acquisitions of anesthesiologist practices during the quarter, and (2) any future anesthesiologist acquisitions were unlikely. This news appeared to be inconsistent with earlier statements that the Company had a robust pipeline of anesthesiologist deals.
This news drove the price of Mednax shares down $8.76, or over 15%, to close at $47.73 that day.
“We’re focused on investors’ losses and Defendants’ apparently misleading statements to Mednax investors about the sustainability of its acquisition-oriented business model,” said Hagens Berman partner Reed Kathrein.
Whistleblowers: Persons with non-public information regarding Mednax should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email MD@hbsslaw.com.
Hagens Berman purchases advertisements on search engines, social media sites and other websites. Transmission of the information contained or available through this website is not intended to create, and receipt does not constitute, an attorney-client relationship. If you seek legal advice or representation by Hagens Berman, you must first enter a formal agreement. All information contained in any transmission is confidential and Hagens Berman agrees to protect information against unauthorized use, publication or disclosure. This site is regulated by the Washington Rules of Professional Conduct.